BNR

Burning Rock Biotech Limited is a Chinese precision oncology company focused on developing and commercializing next-generation sequencing (NGS)-based cancer therapy selection and cancer early detection tests. Headquartered in Guangzhou, China, Burning Rock provides comprehensive genomic profiling services that identify genetic alterations in tumors, enabling oncologists to select targeted therapies, monitor treatment response, detect minimal residual disease, and screen for early-stage cancer. The company operates in the rapidly growing liquid biopsy and precision oncology markets in China. Burning Rock's portfolio includes tissue-based and liquid biopsy-based NGS panels covering various cancer types and clinical applications. OncoScreen panels provide comprehensive genomic profiling of tumors to guide therapy selection, identifying actionable mutations that can be targeted with approved or investigational drugs. The company's liquid biopsy tests analyze circulating tumor DNA (ctDNA) in blood samples for therapy selection, treatment monitoring, resistance mechanism detection, and minimal residual disease assessment. Burning Rock is also developing multi-cancer early detection tests designed to screen asymptomatic individuals for multiple cancer types through blood-based assays. The company operates central laboratories in China equipped with state-of-art NGS technology and has obtained numerous regulatory approvals and certifications. Burning Rock serves hospitals, clinics, and pharmaceutical companies through commercial partnerships and collaborations. The Chinese precision oncology market is growing rapidly driven by increasing cancer incidence, adoption of targeted therapies, expanding insurance coverage for NGS testing, and government initiatives promoting precision medicine. Burning Rock competes with domestic Chinese competitors and international companies including Guardant Health, Foundation Medicine, and others seeking to establish presence in China. Success depends on maintaining technology leadership, securing hospital partnerships, expanding test menu, achieving favorable pricing and reimbursement, conducting clinical validation studies, navigating regulatory requirements, and scaling operations. As a Chinese company listed on NASDAQ, Burning Rock faces additional investor considerations including regulatory compliance across jurisdictions, potential delisting risks, and corporate governance standards.